Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DTIL 
Precision BioSciences Inc (DTIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: DTIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30.5
1 Year Target Price $30.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.46% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.17M USD | Price to earnings Ratio - | 1Y Target Price 30.5 |
Price to earnings Ratio - | 1Y Target Price 30.5 | ||
Volume (30-day avg) 4 | Beta 1.52 | 52 Weeks Range 3.61 - 11.09 | Updated Date 08/28/2025 |
52 Weeks Range 3.61 - 11.09 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.54 | Actual -2.13 |
Profitability
Profit Margin - | Operating Margin (TTM) -121538.89% |
Management Effectiveness
Return on Assets (TTM) -41% | Return on Equity (TTM) -143.89% |
Valuation
Trailing PE - | Forward PE 2.11 | Enterprise Value 26255824 | Price to Sales(TTM) 46.92 |
Enterprise Value 26255824 | Price to Sales(TTM) 46.92 | ||
Enterprise Value to Revenue 20.82 | Enterprise Value to EBITDA -0.27 | Shares Outstanding 11787000 | Shares Floating 10554897 |
Shares Outstanding 11787000 | Shares Floating 10554897 | ||
Percent Insiders 11.28 | Percent Institutions 44.25 |
Upturn AI SWOT
Precision BioSciences Inc
Company Overview
History and Background
Precision BioSciences was founded in 2006. It focuses on developing gene editing technologies to treat diseases. Significant milestones include the development of its ARCUS platform and advancing clinical trials for various therapies.
Core Business Areas
- Allogeneic Cell Therapy: Development of off-the-shelf CAR T cell therapies for cancer, utilizing ARCUS gene editing to improve safety and efficacy.
- In Vivo Gene Editing: Utilizing ARCUS to directly edit genes within the body, targeting genetic diseases and other conditions.
Leadership and Structure
The leadership team includes the CEO, CSO, and CFO. The organizational structure is based on functional areas like research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- PBCAR0191: An allogeneic CAR T-cell therapy targeting CD19 for B-cell malignancies. Currently in clinical development. Market share data unavailable due to being in development stage. Competitors: Novartis (Kymriah), Gilead Sciences (Yescarta).
- In Vivo Gene Editing Programs: Developing in vivo gene editing programs targeting diseases like hepatitis B. Market share data unavailable due to being in development stage. Competitors: Beam Therapeutics, Editas Medicine, Intellia Therapeutics.
Market Dynamics
Industry Overview
The gene editing and cell therapy industry is rapidly growing, driven by technological advancements and increasing demand for novel therapies for genetic diseases and cancer.
Positioning
Precision BioSciences is positioned as a leader in the gene editing field, utilizing its ARCUS platform. Competitive advantages include the precision and versatility of the ARCUS technology, especially with respect to other gene editing tools like CRISPR.
Total Addressable Market (TAM)
The total addressable market for gene editing and cell therapy is expected to reach billions of dollars. Precision BioSciences is positioned to capture a portion of this market through its pipeline of therapies.
Upturn SWOT Analysis
Strengths
- Proprietary ARCUS gene editing platform
- Strong intellectual property portfolio
- Experienced leadership team
- Advancing clinical trials
Weaknesses
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Competition from larger biotech companies
- Limited number of approved products
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of ARCUS platform to new therapeutic areas
- Positive clinical trial results leading to regulatory approval
- Address large unmet medical needs
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene editing technologies
- Economic downturn impacting investment in biotech
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- NTLA
Competitive Landscape
Precision BioSciences faces competition from companies with similar technologies and those developing alternative gene editing platforms. Precision's advantage lies in its ARCUS platform's specificity. Disadvantages include financial resources compared to larger companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth requires specific financial data.
Future Projections: Future projections require specific financial data and analyst reports.
Recent Initiatives: Recent initiatives include advancing clinical trials and expanding partnerships.
Summary
Precision BioSciences is a gene editing company with a promising ARCUS platform, although it has yet to market an FDA approved product. The Company has an experienced leadership team, which is advancing clinical trials and expanding partnerships. They must watch out for potential clinical trial failures and regulatory hurdles as well as competition from other Gene Editing Companies. It could have growth opportunities if it can expand its platforms to other therapeutic areas.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary. Financial data is illustrative and should be verified with official company filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precision BioSciences Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2019-03-28 | President, CEO & Director Mr. Michael Amoroso | ||
Sector Healthcare | Industry Biotechnology | Full time employees 102 | Website https://precisionbiosciences.com |
Full time employees 102 | Website https://precisionbiosciences.com | ||
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.